Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
07 2023
Historique:
received: 10 03 2023
revised: 22 05 2023
accepted: 05 07 2023
medline: 3 8 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: epublish

Résumé

Hürthle cell carcinoma (HCC) is a rare type of thyroid cancer with high rates of distant metastasis and recurrence. Along with the scarcity of effective systemic therapies for HCC, these factors contribute to poor clinical outcomes. The immunologic features of HCC are poorly defined and response rates with immune checkpoint blockade have not been reported. A more comprehensive understanding of the immune landscape and factors that predict response to checkpoint inhibitors is needed. We performed RNA sequencing on 40 tumors to characterize the neoantigen landscape and immune microenvironment of HCC. We analyzed transcriptomic profiles, tumor-infiltrating immune cell populations, and measures of T-cell activation/dysfunction and correlated these to genetic features such as tumor mutation burden, neoantigen burden, mitochondrial mutations, and LOH from chromosomal uniparental disomy. Finally, immune profiles of patients with recurrence were compared with those of patients without recurrence. HCC tumors exhibited low levels of immune infiltration, with the more aggressive widely invasive phenotype associated with more immune depletion. There was a negative correlation between tumor mutation burden, neoantigen burden, programmed cell death ligand 1 (PD-L1) expression, and the immune infiltration score. HCC tumors that exhibited a global LOH from chromosomal uniparental disomy or haploidization had the lowest level of immune infiltration. HCC tumors that recurred displayed an immune-depleted microenvironment associated with global LOH and aerobic glycolysis. These findings offer new insights into the functional immune landscapes and immune microenvironment of HCC. Our data identify potential immunologic vulnerabilities for these understudied and often fatal cancers. The immune landscape of HCC is poorly defined and response rates to immunotherapy have not been reported. The authors found the immune microenvironment in HCC to be depleted. This immunosuppression is associated with a global LOH from haploidization and uniparental disomy, resulting in whole chromosome losses across the genome.

Identifiants

pubmed: 37529400
doi: 10.1158/2767-9764.CRC-23-0120
pii: CRC-23-0120
pmc: PMC10389111
doi:

Substances chimiques

B7-H1 Antigen 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1409-1422

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA172012
Pays : United States

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Références

Bioinformatics. 2012 Feb 1;28(3):311-7
pubmed: 22155872
J Clin Oncol. 2023 Jan 1;41(1):75-85
pubmed: 35867951
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Nat Genet. 2014 Aug;46(8):912-918
pubmed: 25017105
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer. 2003 Mar 1;97(5):1186-94
pubmed: 12599224
Cancer Treat Rev. 2016 Jan;42:47-55
pubmed: 26678514
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Endocr Relat Cancer. 2016 Dec;23(12):X2
pubmed: 27807063
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Front Oncol. 2019 Nov 01;9:1143
pubmed: 31737570
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Bioinformatics. 2014 Oct;30(19):2757-63
pubmed: 24907368
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Nat Biotechnol. 2015 Nov;33(11):1152-8
pubmed: 26372948
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Sci Adv. 2022 Jun 24;8(25):eabn9699
pubmed: 35731870
Front Immunol. 2019 Aug 07;10:1878
pubmed: 31440253
JAMA Oncol. 2016 Sep 1;2(9):1179-86
pubmed: 27243803
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cancer Control. 1997 Jan;4(1):13-17
pubmed: 10762998
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Am J Hum Genet. 2012 Nov 2;91(5):839-48
pubmed: 23103226
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Cancer Cell. 2018 Aug 13;34(2):242-255.e5
pubmed: 30107175
Cancer Cell. 2018 Aug 13;34(2):256-270.e5
pubmed: 30107176
Am J Surg. 1996 Dec;172(6):692-4
pubmed: 8988680
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
N Engl J Med. 2017 Feb 9;376(6):596
pubmed: 28177863
Nat Commun. 2013;4:2612
pubmed: 24113773
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Cancer. 2006 Apr 15;106(8):1669-76
pubmed: 16534796
Cancer. 1998 Dec 15;83(12):2638-48
pubmed: 9874472
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Front Immunol. 2018 Nov 12;9:2564
pubmed: 30483253
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585

Auteurs

Ian Ganly (I)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Fengshen Kuo (F)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Vladimir Makarov (V)

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.

Yiyu Dong (Y)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Ronald Ghossein (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Bin Xu (B)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Luc G T Morris (LGT)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Timothy A Chan (TA)

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH